Cara Therapeutics Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammat

Company Highlights
Year Founded

2004

icon-altEmployees

55

Location (HQ)

USA

Since Last Funding

1 year

Monthly Website Visitors

14.8K

icon-altTotal Investment Amt

$500M

Last Funding Round

Post Ipo Debt

icon-altMoM Headcount Growth

-3.5%

icon-altYoY Headcount Growth

-49.03%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Health Care

Therapeutics

Biotechnology

Biotechnology Research